Executives

meet our team

Gary Pasternack, MD, PhD

Chief Executive Officer (C.E.O.)

Gary Pasternack, MD, PhD is a seasoned biotech executive with a history of identifying opportunities for challenging, innovative technologies and driving them to product stage and commercialization. As one example, he is a co-founder of Intralytix where he identified food safety opportunities for bacteriophages, obtained initial funding for the company, and helped the company obtain FDA approval for its initial products involving the application of bacteriophages (live viruses) to food to eliminate food-borne bacterial pathogens. Most recently, after joining Asklepion in 2008, he led Asklepion’s successful efforts to obtain FDA and EMA approval for Cholbam® (cholic acid) in the US and Kolbam® (cholic acid) in the EU based principally upon retrospective studies of patients with inborn errors of bile acid metabolism, earning a Rare Pediatric Disease Priority Review Voucher from the FDA. Forming a team with Jeff Courtney, Asklepion’s C.O.O., the pair successfully negotiated the sale of Cholbam/Kolbam to Retrophin. Dr. Pasternack is a board-certified pathologist who maintains an adjunct academic appointment at his alma mater, Johns Hopkins. He is an inventor on 29 issued US patents.

Terrance Coyne, MD

Chief Medical Officer (C.M.O.)

Dr. Coyne brings more than 25 years of Pharmaceutical R&D, medical affairs and clinical research experience to Asklepion Pharmaceuticals, LLC. More than two-thirds of Dr. Coyne’s experience has been as the Chief Medical Officer for the following pharmaceutical companies: Greer Laboratories, Ventrus Biosciences, Inc., Encysive Pharmaceuticals, Metaphore Pharmaceuticals, Celltech Medeva Pharmaceuticals, and 3M Pharmaceuticals. Dr. Coyne also brings valuable experience from the perspective of mergers, acquisitions and funding from Ferghana Partners, Inc. Dr. Coyne received his M.D. degree from the University of Wisconsin, Madison, WI.

Gary Pyner, MBA

Director of Commercial Affairs

Mr. Pyner brings more than 25 years of global pharmaceutical sales and orphan drug marketing experience to Asklepion Pharmaceuticals, LLC. Most recently Mr. Pyner was founder and CEO of N3Q Consulting, LLC, which provides executive-level guidance regarding orphan drug commercialization to a number of start-up pharmaceutical companies. Prior to this endeavor, he was the V.P. of Marketing at Ikaria (formerly INO Therapeutics), where he was responsible for all commercial and reimbursement activities for the orphan drug INOmax®. Prior to that, Mr. Pyner was the Senior Director of Marketing of Diversified Products at Pfizer. Mr. Pyner received his MBA in Pharmaceutical Marketing from Fairleigh Dickinson University.

Keith Ryan

Director of Regulatory Affairs

Mr. Ryan brings more than 25 years of pharmaceutical regulatory affairs experience to Asklepion Pharmaceuticals, LLC. His regulatory experience covers multiple therapeutic areas and orphan drugs. He has worked primarily on the brand side of the pharmaceutical industry with Eximias, Sanofi-Aventis, Grunenthal, USA and Cote Orphan Consulting. Mr. Ryan also has extensive experience from the CRO side of the regulatory business, with time spent at IBRD-Rostrum and Omnicare. Mr. Ryan holds a B.S. in Microbiology with graduate course work in toxicology, biostatistics, epidemiology, virology and biochemistry at the National Institutes of Health.

Cindy Zychowicz

Director of Clinical Operations

Ms. Zychowicz brings almost 30 years of academic, biotechnology, pharmaceutical, and device experience to Asklepion Pharmaceuticals, LLC. Her experience covers many therapeutic areas and all phases of clinical research, including work with neonatal and pediatric populations. Ms. Zychowicz has held positions at Children’s Hospital of Philadelphia, the University of Maryland Hospital, and various pharmaceutical and biotechnology companies, including Otsuka America Pharmaceutical, Inc., and Wellstat Therapeutics Corporation, in addition to positions at CROs. Ms. Zychowicz holds a Bachelor of Arts degree in Psychology.

Elizabeth Monnot-Chase, PhD

Director of CMC, Quality

Dr. Monnot-Chase brings 25 years of critical formulation, analytical method development, quality systems design, validation and stability determinations to Asklepion Pharmaceuticals, LLC.  Prior to joining Asklepion, Dr. Monnot-Chase was the Associate Director-Chemistry, Manufacture and Controls at Shire, plc./ViroPharma, Inc.  Dr. Monnot-Chase previously held management positions at Cephalon, Inc., Cardinal Health/Magellan Laboratories and G.D. Searle & Company.  Dr. Monnot-Chase received her Ph.D. in Pharmaceutical Chemistry and Pharmaceutical Analysis and her M.S. in Pharmaceutical Chemistry from the University of Kansas.